NCBI . NLM . NIH . GOV {}

Matching Content Categories {📚}

• Education
• Health & Fitness
• Science

Content Management System {📝}

What CMS is ncbi.nlm.nih.gov built with?

Custom-built

No common CMS systems were detected on Ncbi.nlm.nih.gov, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of ncbi.nlm.nih.gov audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Ncbi.nlm.nih.gov Make Money? {💸}

We find it hard to spot revenue streams.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Ncbi.nlm.nih.gov could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

doi, ipilimumab, nivolumab, pubmed, google, scholar, cancer, patients, combination, ctla, phase, pmc, melanoma, article, free, cell, advanced, metastatic, months, study, rate, median, carcinoma, oncol, cells, pfs, orr, efficacy, trial, treatment, med, versus, death, response, blockade, studies, lung, pembrolizumab, engl, immune, activation, lancet, nejmoa, clinical, treated, blockers, therapy, grade, rates, table,

Topics {✒️}

dna mismatch repair-deficient dna repair deficiency hazard ratio microsatellite instability high protein kinase dna-repair defects small-cell lung cancer pd-1 receptor-deficient mice antigen presenting cells cis-pd-l1/cd80 interactions ar-v7 positive gastro-oesophageal junction cancer progression-free survival regulatory t-cells advanced renal-cell carcinoma stimulating t-cell proliferation extracellular n-terminal igv itim motif-carrying immunoreceptor phosphatidylinositol 3-kinase sustains t-cell anergy drd negative tumors anti-tumor immune responses recurrent squamous-cell carcinoma transmembrane protein belonging pmc beta search anti-tumor immune response drd positive tumors interleukin-2 receptor signaling tumor microenvironment immune-related adverse event pmc copyright notice monoclonal anti pd-1antibodies programmed cell death ar-v7 mapk pathways [26–30] immune-related adverse events pi3k/akt pathway ctla-4-deficient mice peripheral t-cell tolerance activated t-cells �high-risk’ melanoma [31–38] pd-l1 negative tumors anti-ctla-4 antibodies resulted anti-pd-1/pd-l1 renal cell carcinoma pd-1/pd-l1 pathway nkt cells merkel cell carcinoma pd-l1 positive tumors pd-1/pd-l1 blockers

Social Networks {👍}(6)

• https://twitter.com/ncbi
• https://www.facebook.com/ncbi.nlm
• https://www.linkedin.com/company/ncbinlm
• https://twitter.com/nlm_nih
• https://www.facebook.com/nationallibraryofmedicine
• https://www.youtube.com/user/NLMNIH

External Links {🔗}(249)

• Check the income stats for https://doi.org/10.1186/s13046-019-1259-z
• How much revenue does http://creativecommons.org/licenses/by/4.0/ produce monthly?
• http://creativecommons.org/publicdomain/zero/1.0/ income
• What's the income generated by https://clinicaltrials.gov/ct2/show/NCT01024231 each month?
• What's the total monthly financial gain of https://clinicaltrials.gov/ct2/show/NCT01927419?
• How much revenue does https://clinicaltrials.gov/ct2/show/NCT01844505 produce monthly?
• What's the monthly money flow for https://clinicaltrials.gov/ct2/show/NCT02320058?
• Explore the financials of https://clinicaltrials.gov/ct2/show/NCT01783938
• Income figures for https://clinicaltrials.gov/ct2/show/NCT02231749
• Check the income stats for https://clinicaltrials.gov/ct2/show/NCT02060188
• How much revenue does https://clinicaltrials.gov/ct2/show/NCT02000947 bring in?
• Learn about the earnings of https://clinicaltrials.gov/ct2/show/NCT01928394
• What's https://clinicaltrials.gov/ct2/show/NCT01454102's gross income?
• How much does https://clinicaltrials.gov/ct2/show/NCT02659059 rake in every month?
• How much does https://clinicaltrials.gov/ct2/show/NCT02477826 make?
• How much cash flow does https://clinicaltrials.gov/ct2/show/NCT03048474 have monthly?
• Find out how much https://clinicaltrials.gov/ct2/show/NCT02716272 earns monthly
• Explore the financials of https://clinicaltrials.gov/ct2/show/NCT02500797
• What's the monthly money flow for https://clinicaltrials.gov/ct2/show/NCT02601014?
• How much profit is https://doi.org/10.4049/jimmunol.1490019 making per month?
• How much income is https://scholar.google.com/scholar_lookup?journal=J%20Immunol.&title=IL-2:%20the%20first%20effective%20immunotherapy%20for%20human%20cancer&author=SA%20Rosenberg&volume=192&issue=12&publication_year=2014&pages=5451-5458&pmid=24907378&doi=10.4049/jimmunol.1490019& earning monthly?
• How much does https://scholar.google.com/scholar_lookup?title=Interleukin-2.%20Immunotherapy%20of%20melanoma&author=A%20Rotte&author=M%20Bhandaru&publication_year=2016& gross monthly?
• What's the financial gain of https://scholar.google.com/scholar_lookup?title=Interferon-a2b.%20Immunotherapy%20of%20melanoma&author=A%20Rotte&author=M%20Bhandaru&publication_year=2016&?
• Earnings of https://doi.org/10.1007/s10555-014-9542-0
• How much does https://scholar.google.com/scholar_lookup?journal=Cancer%20Metastasis%20Rev.&title=Immunotherapy%20of%20melanoma:%20present%20options%20and%20future%20promises&author=A%20Rotte&author=M%20Bhandaru&author=Y%20Zhou&author=KJ%20McElwee&volume=34&issue=1&publication_year=2015&pages=115-128&pmid=25589384&doi=10.1007/s10555-014-9542-0& earn?
• Monthly income for https://doi.org/10.1053/j.seminoncol.2015.05.014
• How much does https://scholar.google.com/scholar_lookup?journal=Semin%20Oncol.&title=Agonists%20of%20Co-stimulation%20in%20Cancer%20Immunotherapy%20Directed%20Against%20CD137,%20OX40,%20GITR,%20CD27,%20CD28,%20and%20ICOS&author=MF%20Sanmamed&author=F%20Pastor&author=A%20Rodriguez&author=JL%20Perez-Gracia&author=ME%20Rodriguez-Ruiz&volume=42&issue=4&publication_year=2015&pages=640-655&pmid=26320067&doi=10.1053/j.seminoncol.2015.05.014& net monthly?
• What's the monthly money flow for https://doi.org/10.1016/j.cell.2018.09.035?
• What's the financial gain of https://scholar.google.com/scholar_lookup?journal=Cell.&title=A%20Paradigm%20Shift%20in%20Cancer%20Immunotherapy:%20From%20Enhancement%20to%20Normalization&author=MF%20Sanmamed&author=L%20Chen&volume=175&issue=2&publication_year=2018&pages=313-326&pmid=30290139&doi=10.1016/j.cell.2018.09.035&?
• Check the income stats for https://doi.org/10.1038/s12276-018-0191-1
• How much does https://scholar.google.com/scholar_lookup?journal=Exp%20Mol%20Med.&title=Immune%20checkpoint%20inhibitors:%20recent%20progress%20and%20potential%20biomarkers&author=P%20Darvin&author=SM%20Toor&author=V%20Sasidharan%20Nair&author=E%20Elkord&volume=50&issue=12&publication_year=2018&pages=165&pmid=30546008&doi=10.1038/s12276-018-0191-1& bring in each month?
• What's the profit of https://doi.org/10.1186/s13046-019-1153-8?
• What's https://scholar.google.com/scholar_lookup?journal=J%20Exp%20Clin%20Cancer%20Res.&title=Therapeutic%20challenges%20and%20current%20immunomodulatory%20strategies%20in%20targeting%20the%20immunosuppressive%20pancreatic%20tumor%20microenvironment&author=CK%20Looi&author=FF%20Chung&author=CO%20Leong&author=SF%20Wong&author=R%20Rosli&volume=38&issue=1&publication_year=2019&pages=162&pmid=30987642&doi=10.1186/s13046-019-1153-8&'s gross income?
• Explore the financials of https://doi.org/10.14302/issn.2471-2175.jdrt-17-1760
• What's the profit of https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Dermatologic%20Research%20and%20Therapy.&title=Blockade%20of%20programmed%20cell%20death%20protein-1%20pathway%20for%20the%20treatment%20of%20melanoma&author=M%20Bhandaru&author=A%20Rotte&volume=1&issue=2&publication_year=2017&pages=1-11&doi=10.14302/issn.2471-2175.jdrt-17-1760&?
• Financial intake of https://doi.org/10.1186/s13046-019-1085-3
• How much money does https://scholar.google.com/scholar_lookup?journal=J%20Exp%20Clin%20Cancer%20Res.&title=Challenges%20and%20potential%20of%20PD-1/PD-L1%20checkpoint%20blockade%20immunotherapy%20for%20glioblastoma&author=X%20Wang&author=G%20Guo&author=H%20Guan&author=Y%20Yu&author=J%20Lu&volume=38&issue=1&publication_year=2019&pages=87&pmid=30777100&doi=10.1186/s13046-019-1085-3& make?
• https://doi.org/10.1016/j.intimp.2018.06.001's total income per month
• How much does https://scholar.google.com/scholar_lookup?journal=Int%20Immunopharmacol.&title=Immune%20checkpoint%20blockade%20therapy%20for%20cancer:%20An%20overview%20of%20FDA-approved%20immune%20checkpoint%20inhibitors&author=KM%20Hargadon&author=CE%20Johnson&author=CJ%20Williams&volume=62&publication_year=2018&pages=29-39&pmid=29990692&doi=10.1016/j.intimp.2018.06.001& rake in every month?
• Get to know https://doi.org/10.1186/s13046-018-0937-6's earnings
• What's the financial outcome of https://scholar.google.com/scholar_lookup?journal=J%20Exp%20Clin%20Cancer%20Res.&title=Nobel%20committee%20honors%20tumor%20immunologists&author=A%20Rotte&author=G%20D'Orazi&author=M%20Bhandaru&volume=37&issue=1&publication_year=2018&pages=262&pmid=30376854&doi=10.1186/s13046-018-0937-6&?
• Get to know what's the income of https://doi.org/10.1093/annonc/mdx686
• Revenue of https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol.&title=Mechanistic%20overview%20of%20immune%20checkpoints%20to%20support%20the%20rational%20design%20of%20their%20combinations%20in%20cancer%20immunotherapy&author=A%20Rotte&author=JY%20Jin&author=V%20Lemaire&volume=29&issue=1&publication_year=2018&pages=71-83&pmid=29069302&doi=10.1093/annonc/mdx686&
• See how much https://doi.org/10.1155/2013/857519 makes per month
• How much does https://scholar.google.com/scholar_lookup?journal=Scientifica%20(Cairo).&title=Immune-mediated%20adverse%20events%20associated%20with%20ipilimumab%20ctla-4%20blockade%20therapy:%20the%20underlying%20mechanisms%20and%20clinical%20management&author=A%20Tarhini&volume=2013&publication_year=2013&pages=857519&pmid=24278787&doi=10.1155/2013/857519& make?
• https://doi.org/10.1016/j.ejca.2015.11.016 income
• https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Cancer.&title=Immune-related%20adverse%20events%20with%20immune%20checkpoint%20blockade:%20a%20comprehensive%20review&author=JM%20Michot&author=C%20Bigenwald&author=S%20Champiat&author=M%20Collins&author=F%20Carbonnel&volume=54&publication_year=2016&pages=139-148&pmid=26765102&doi=10.1016/j.ejca.2015.11.016& income
• Discover the revenue of https://doi.org/10.1038/328267a0
• How much does https://scholar.google.com/scholar_lookup?journal=Nature.&title=A%20new%20member%20of%20the%20immunoglobulin%20superfamily--CTLA-4&author=JF%20Brunet&author=F%20Denizot&author=MF%20Luciani&author=M%20Roux-Dosseto&author=M%20Suzan&volume=328&issue=6127&publication_year=1987&pages=267-270&pmid=3496540&doi=10.1038/328267a0& make?
• Explore the financials of https://scholar.google.com/scholar_lookup?journal=J%20Immunol.&title=Regulation%20of%20CTLA-4%20expression%20during%20T%20cell%20activation&author=D%20Perkins&author=Z%20Wang&author=C%20Donovan&author=H%20He&author=D%20Mark&volume=156&issue=11&publication_year=1996&pages=4154-4159&pmid=8666782&
• What are the earnings of https://scholar.google.com/scholar_lookup?journal=J%20Immunol.&title=Regulation%20of%20surface%20and%20intracellular%20expression%20of%20CTLA4%20on%20mouse%20T%20cells&author=ML%20Alegre&author=PJ%20Noel&author=BJ%20Eisfelder&author=E%20Chuang&author=MR%20Clark&volume=157&issue=11&publication_year=1996&pages=4762-4770&pmid=8943377&?
• What's the total monthly financial gain of https://doi.org/10.1038/nrc3239?
• How much does https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Cancer.&title=The%20blockade%20of%20immune%20checkpoints%20in%20cancer%20immunotherapy&author=DM%20Pardoll&volume=12&issue=4&publication_year=2012&pages=252-264&pmid=22437870&doi=10.1038/nrc3239& bring in each month?
• How much money does https://doi.org/10.1111/j.1600-065X.2008.00662.x generate?
• How much income does https://scholar.google.com/scholar_lookup?journal=Immunol%20Rev.&title=Control%20of%20peripheral%20T-cell%20tolerance%20and%20autoimmunity%20via%20the%20CTLA-4%20and%20PD-1%20pathways&author=BT%20Fife&author=JA%20Bluestone&volume=224&publication_year=2008&pages=166-182&pmid=18759926&doi=10.1111/j.1600-065X.2008.00662.x& have?
• How much profit does https://doi.org/10.1038/35069118 generate?
• What's the income of https://scholar.google.com/scholar_lookup?journal=Nature.&title=Crystal%20structure%20of%20the%20B7-1/CTLA-4%20complex%20that%20inhibits%20human%20immune%20responses&author=CC%20Stamper&author=Y%20Zhang&author=JF%20Tobin&author=DV%20Erbe&author=S%20Ikemizu&volume=410&issue=6828&publication_year=2001&pages=608-611&pmid=11279502&doi=10.1038/35069118&?
• What's the financial intake of https://doi.org/10.1126/science.1160062?
• What's the financial intake of https://scholar.google.com/scholar_lookup?journal=Science.&title=CTLA-4%20control%20over%20Foxp3+%20regulatory%20T%20cell%20function&author=K%20Wing&author=Y%20Onishi&author=P%20Prieto-Martin&author=T%20Yamaguchi&author=M%20Miyara&volume=322&issue=5899&publication_year=2008&pages=271-275&pmid=18845758&doi=10.1126/science.1160062&?
• Revenue of https://doi.org/10.1084/jem.182.2.459
• What is the monthly revenue of https://scholar.google.com/scholar_lookup?journal=J%20Exp%20Med.&title=CD28%20and%20CTLA-4%20have%20opposing%20effects%20on%20the%20response%20of%20T%20cells%20to%20stimulation&author=MF%20Krummel&author=JP%20Allison&volume=182&issue=2&publication_year=1995&pages=459-465&pmid=7543139&doi=10.1084/jem.182.2.459&?
• What is the earnings of https://doi.org/10.1126/science.271.5256.1734?
• https://scholar.google.com/scholar_lookup?journal=Science.&title=Enhancement%20of%20antitumor%20immunity%20by%20CTLA-4%20blockade&author=DR%20Leach&author=MF%20Krummel&author=JP%20Allison&volume=271&issue=5256&publication_year=1996&pages=1734-1736&pmid=8596936&doi=10.1126/science.271.5256.1734&'s financial summary
• How much revenue does https://doi.org/10.1016/S1074-7613(00)80406-9 produce monthly?
• How much does https://scholar.google.com/scholar_lookup?journal=Immunity.&title=Lymphoproliferation%20in%20CTLA-4-deficient%20mice%20is%20mediated%20by%20costimulation-dependent%20activation%20of%20CD4+%20T%20cells&author=CA%20Chambers&author=TJ%20Sullivan&author=JP%20Allison&volume=7&issue=6&publication_year=1997&pages=885-895&pmid=9430233&doi=10.1016/S1074-7613(00)80406-9& bring in each month?
• How much does https://doi.org/10.1189/jlb.1212621 pull in monthly?
• How much does https://scholar.google.com/scholar_lookup?journal=J%20Leukoc%20Biol.&title=At%20the%20bench:%20preclinical%20rationale%20for%20CTLA-4%20and%20PD-1%20blockade%20as%20cancer%20immunotherapy&author=AM%20Intlekofer&author=CB%20Thompson&volume=94&issue=1&publication_year=2013&pages=25-39&pmid=23625198&doi=10.1189/jlb.1212621& earn?
• How much revenue does https://doi.org/10.4049/jimmunol.175.1.177 generate?
• What's the income generated by https://scholar.google.com/scholar_lookup?journal=J%20Immunol.&title=B7-independent%20inhibition%20of%20T%20cells%20by%20CTLA-4&author=S%20Chikuma&author=AK%20Abbas&author=JA%20Bluestone&volume=175&issue=1&publication_year=2005&pages=177-181&pmid=15972645&doi=10.4049/jimmunol.175.1.177& each month?
• https://doi.org/10.1371/journal.pone.0003842's financial summary
• How much does https://scholar.google.com/scholar_lookup?journal=PLoS%20One.&title=CTLA-4%20activation%20of%20phosphatidylinositol%203-kinase%20(PI%203-K)%20and%20protein%20kinase%20B%20(PKB/AKT)%20sustains%20T-cell%20anergy%20without%20cell%20death&author=H%20Schneider&author=E%20Valk&author=R%20Leung&author=CE%20Rudd&volume=3&issue=12&publication_year=2008&pages=e3842&pmid=19052636&doi=10.1371/journal.pone.0003842& generate monthly?
• How profitable is https://doi.org/10.1002/(SICI)1521-4141(199903)29:03<838::AID-IMMU838>3.0.CO;2-P?
• How much cash flow does https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Immunol.&title=CTLA4%20ligation%20attenuates%20AP-1,%20NFAT%20and%20NF-kappaB%20activity%20in%20activated%20T%20cells&author=JH%20Fraser&author=M%20Rincon&author=KD%20McCoy&author=G%20Le%20Gros&volume=29&issue=3&publication_year=1999&pages=838-844&pmid=10092086&doi=10.1002/(SICI)1521-4141(199903)29:03<838::AID-IMMU838>3.0.CO;2-P& have monthly?
• What's the monthly income of https://doi.org/10.1007/978-1-4939-8958-4_4?
• What's https://scholar.google.com/scholar_lookup?journal=Methods%20Mol%20Biol.&title=Monoclonal%20Antibodies%20for%20the%20Treatment%20of%20Melanoma:%20Present%20and%20Future%20Strategies&author=M%20Bhandaru&author=A%20Rotte&volume=1904&publication_year=2019&pages=83-108&pmid=30539467&doi=10.1007/978-1-4939-8958-4_4&'s gross income?
• https://doi.org/10.1016/S1470-2045(17)30231-0's revenue stream
• What's the financial gain of https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol.&title=Ipilimumab%2010%20mg/kg%20versus%20ipilimumab%203%20mg/kg%20in%20patients%20with%20unresectable%20or%20metastatic%20melanoma:%20a%20randomised,%20double-blind,%20multicentre,%20phase%203%20trial&author=PA%20Ascierto&author=M%20Del%20Vecchio&author=C%20Robert&author=A%20Mackiewicz&author=V%20Chiarion-Sileni&volume=18&issue=5&publication_year=2017&pages=611-622&pmid=28359784&doi=10.1016/S1470-2045(17)30231-0&?
• What's the monthly income of https://doi.org/10.1093/annonc/mdu577?
• What's the financial gain of https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol.&title=Three-year%20follow-up%20of%20advanced%20melanoma%20patients%20who%20received%20ipilimumab%20plus%20fotemustine%20in%20the%20Italian%20Network%20for%20Tumor%20Biotherapy%20(NIBIT)-M1%20phase%20II%20study&author=AM%20Di%20Giacomo&author=PA%20Ascierto&author=P%20Queirolo&author=L%20Pilla&author=R%20Ridolfi&volume=26&issue=4&publication_year=2015&pages=798-803&pmid=25538176&doi=10.1093/annonc/mdu577&?
• Monthly income for https://doi.org/10.1056/NEJMoa1611299
• Income figures for https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med.&title=Prolonged%20Survival%20in%20Stage%20III%20Melanoma%20with%20Ipilimumab%20Adjuvant%20Therapy&author=AM%20Eggermont&author=V%20Chiarion-Sileni&author=JJ%20Grob&author=R%20Dummer&author=JD%20Wolchok&volume=375&issue=19&publication_year=2016&pages=1845-1855&pmid=27717298&doi=10.1056/NEJMoa1611299&
• What is the monthly revenue of https://doi.org/10.1016/S1470-2045(15)70122-1?
• What's the revenue for https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol.&title=Adjuvant%20ipilimumab%20versus%20placebo%20after%20complete%20resection%20of%20high-risk%20stage%20III%20melanoma%20(EORTC%2018071):%20a%20randomised,%20double-blind,%20phase%203%20trial&author=AM%20Eggermont&author=V%20Chiarion-Sileni&author=JJ%20Grob&author=R%20Dummer&author=JD%20Wolchok&volume=16&issue=5&publication_year=2015&pages=522-530&pmid=25840693&doi=10.1016/S1470-2045(15)70122-1&?
• How much money does https://doi.org/10.1056/NEJMoa1003466 generate?
• Learn how profitable https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med.&title=Improved%20survival%20with%20ipilimumab%20in%20patients%20with%20metastatic%20melanoma&author=FS%20Hodi&author=SJ%20O'Day&author=DF%20McDermott&author=RW%20Weber&author=JA%20Sosman&volume=363&issue=8&publication_year=2010&pages=711-723&pmid=20525992&doi=10.1056/NEJMoa1003466& is on a monthly basis
• Find out how much https://doi.org/10.1056/NEJMoa1104621 earns monthly
• What's the income of https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med.&title=Ipilimumab%20plus%20dacarbazine%20for%20previously%20untreated%20metastatic%20melanoma&author=C%20Robert&author=L%20Thomas&author=I%20Bondarenko&author=S%20O'Day&author=J%20Weber&volume=364&issue=26&publication_year=2011&pages=2517-26&pmid=21639810&doi=10.1056/NEJMoa1104621&?
• How much does https://doi.org/10.1016/S1470-2045(09)70334-1 net monthly?
• https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol.&title=Ipilimumab%20monotherapy%20in%20patients%20with%20pretreated%20advanced%20melanoma:%20a%20randomised,%20double-blind,%20multicentre,%20phase%202,%20dose-ranging%20study&author=JD%20Wolchok&author=B%20Neyns&author=G%20Linette&author=S%20Negrier&author=J%20Lutzky&volume=11&issue=2&publication_year=2010&pages=155-164&pmid=20004617&doi=10.1016/S1470-2045(09)70334-1&'s total income per month
• https://doi.org/10.1002/j.1460-2075.1992.tb05481.x's revenue stream
• How much does https://scholar.google.com/scholar_lookup?journal=EMBO%20J.&title=Induced%20expression%20of%20PD-1,%20a%20novel%20member%20of%20the%20immunoglobulin%20gene%20superfamily,%20upon%20programmed%20cell%20death&author=Y%20Ishida&author=Y%20Agata&author=K%20Shibahara&author=T%20Honjo&volume=11&issue=11&publication_year=1992&pages=3887-3895&pmid=1396582&doi=10.1002/j.1460-2075.1992.tb05481.x& bring in each month?
• How much does https://doi.org/10.1084/jem.20090847 bring in each month?
• What's the financial intake of https://scholar.google.com/scholar_lookup?journal=J%20Exp%20Med.&title=PD-L1%20regulates%20the%20development,%20maintenance,%20and%20function%20of%20induced%20regulatory%20T%20cells&author=LM%20Francisco&author=VH%20Salinas&author=KE%20Brown&author=VK%20Vanguri&author=GJ%20Freeman&volume=206&issue=13&publication_year=2009&pages=3015-3029&pmid=20008522&doi=10.1084/jem.20090847&?
• Get to know https://doi.org/10.1038/85330's earnings
• What's the profit of https://scholar.google.com/scholar_lookup?journal=Nat%20Immunol.&title=PD-L2%20is%20a%20second%20ligand%20for%20PD-1%20and%20inhibits%20T%20cell%20activation&author=Y%20Latchman&author=CR%20Wood&author=T%20Chernova&author=D%20Chaudhary&author=M%20Borde&volume=2&issue=3&publication_year=2001&pages=261-268&pmid=11224527&doi=10.1038/85330&?
• How much profit is https://doi.org/10.1146/annurev.immunol.26.021607.090331 making per month?
• Monthly income for https://scholar.google.com/scholar_lookup?journal=Annu%20Rev%20Immunol.&title=PD-1%20and%20its%20ligands%20in%20tolerance%20and%20immunity&author=ME%20Keir&author=MJ%20Butte&author=GJ%20Freeman&author=AH%20Sharpe&volume=26&publication_year=2008&pages=677-704&pmid=18173375&doi=10.1146/annurev.immunol.26.021607.090331&
• How much does https://doi.org/10.1111/j.1600-065X.2010.00923.x rake in every month?
• How much income does https://scholar.google.com/scholar_lookup?journal=Immunological%20Reviews.&title=The%20PD-1%20pathway%20in%20tolerance%20and%20autoimmunity&author=LM%20Francisco&author=PT%20Sage&author=AH%20Sharpe&volume=236&issue=1&publication_year=2010&pages=219-242&pmid=20636820&doi=10.1111/j.1600-065X.2010.00923.x& have?
• How much profit does https://doi.org/10.4049/jimmunol.165.3.1352 generate?
• What's the total monthly financial gain of https://scholar.google.com/scholar_lookup?journal=J%20Immunol.&title=CTLA-4%20(CD152)%20can%20inhibit%20T%20cell%20activation%20by%20two%20different%20mechanisms%20depending%20on%20its%20level%20of%20cell%20surface%20expression&author=BM%20Carreno&author=F%20Bennett&author=TA%20Chau&author=V%20Ling&author=D%20Luxenberg&volume=165&issue=3&publication_year=2000&pages=1352-1356&pmid=10903737&doi=10.4049/jimmunol.165.3.1352&?
• Earnings of https://doi.org/10.1126/science.aav7062
• What is the earnings of https://doi.org/10.1016/j.immuni.2010.08.004?
• How much profit is https://scholar.google.com/scholar_lookup?journal=Immunity.&title=Interleukin-2%20receptor%20signaling:%20at%20the%20interface%20between%20tolerance%20and%20immunity&author=TR%20Malek&author=I%20Castro&volume=33&issue=2&publication_year=2010&pages=153-165&pmid=20732639&doi=10.1016/j.immuni.2010.08.004& making per month?
• What's the income generated by https://doi.org/10.4049/jimmunol.170.2.711 each month?
• What are the total earnings of https://scholar.google.com/scholar_lookup?journal=J%20Immunol.&title=Program%20death-1%20engagement%20upon%20TCR%20activation%20has%20distinct%20effects%20on%20costimulation%20and%20cytokine-driven%20proliferation:%20attenuation%20of%20ICOS,%20IL-4,%20and%20IL-21,%20but%20not%20CD28,%20IL-7,%20and%20IL-15%20responses&author=F%20Bennett&author=D%20Luxenberg&author=V%20Ling&author=IM%20Wang&author=K%20Marquette&volume=170&issue=2&publication_year=2003&pages=711-718&pmid=12517932&doi=10.4049/jimmunol.170.2.711&?
• https://doi.org/10.1016/S1074-7613(00)80089-8's total income per month
• How much profit does https://scholar.google.com/scholar_lookup?journal=Immunity.&title=Development%20of%20lupus-like%20autoimmune%20diseases%20by%20disruption%20of%20the%20PD-1%20gene%20encoding%20an%20ITIM%20motif-carrying%20immunoreceptor&author=H%20Nishimura&author=M%20Nose&author=H%20Hiai&author=N%20Minato&author=T%20Honjo&volume=11&issue=2&publication_year=1999&pages=141-151&pmid=10485649&doi=10.1016/S1074-7613(00)80089-8& make?
• How much does https://doi.org/10.1126/science.291.5502.319 pull in?
• Monthly income for https://scholar.google.com/scholar_lookup?journal=Science.&title=Autoimmune%20dilated%20cardiomyopathy%20in%20PD-1%20receptor-deficient%20mice&author=H%20Nishimura&author=T%20Okazaki&author=Y%20Tanaka&author=K%20Nakatani&author=M%20Hara&volume=291&issue=5502&publication_year=2001&pages=319-322&pmid=11209085&doi=10.1126/science.291.5502.319&
• What's the monthly money flow for https://doi.org/10.1056/NEJMoa1412082?
• What are the total earnings of https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med.&title=Nivolumab%20in%20previously%20untreated%20melanoma%20without%20BRAF%20mutation&author=C%20Robert&author=GV%20Long&author=B%20Brady&author=C%20Dutriaux&author=M%20Maio&volume=372&issue=4&publication_year=2015&pages=320-330&pmid=25399552&doi=10.1056/NEJMoa1412082&?
• Find out how much https://doi.org/10.1016/S1470-2045(15)70076-8 earns monthly
• What is the earnings of https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol.&title=Nivolumab%20versus%20chemotherapy%20in%20patients%20with%20advanced%20melanoma%20who%20progressed%20after%20anti-CTLA-4%20treatment%20(CheckMate%20037):%20a%20randomised,%20controlled,%20open-label,%20phase%203%20trial&author=JS%20Weber&author=SP%20D'Angelo&author=D%20Minor&author=FS%20Hodi&author=R%20Gutzmer&volume=16&issue=4&publication_year=2015&pages=375-384&pmid=25795410&doi=10.1016/S1470-2045(15)70076-8&?
• Learn about the earnings of https://doi.org/10.1056/NEJMoa1411087
• Monthly income for https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med.&title=PD-1%20blockade%20with%20nivolumab%20in%20relapsed%20or%20refractory%20Hodgkin's%20lymphoma&author=SM%20Ansell&author=AM%20Lesokhin&author=I%20Borrello&author=A%20Halwani&author=EC%20Scott&volume=372&issue=4&publication_year=2015&pages=311-319&pmid=25482239&doi=10.1056/NEJMoa1411087&
• How much does https://doi.org/10.1056/NEJMoa1507643 rake in every month?
• How much does https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med.&title=Nivolumab%20versus%20Docetaxel%20in%20Advanced%20Nonsquamous%20Non-Small-Cell%20Lung%20Cancer&author=H%20Borghaei&author=L%20Paz-Ares&author=L%20Horn&author=DR%20Spigel&author=M%20Steins&volume=373&issue=17&publication_year=2015&pages=1627-1639&pmid=26412456&doi=10.1056/NEJMoa1507643& bring in each month?
• How much does https://doi.org/10.1056/NEJMoa1504627 bring in each month?
• How much does https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med.&title=Nivolumab%20versus%20Docetaxel%20in%20Advanced%20Squamous-Cell%20Non-Small-Cell%20Lung%20Cancer&author=J%20Brahmer&author=KL%20Reckamp&author=P%20Baas&author=L%20Crino&author=WE%20Eberhardt&volume=373&issue=2&publication_year=2015&pages=123-135&pmid=26028407&doi=10.1056/NEJMoa1504627& bring in each month?
• What's the income of https://doi.org/10.1056/NEJMoa1613493?
• What's the revenue for https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med.&title=First-Line%20Nivolumab%20in%20Stage%20IV%20or%20Recurrent%20Non-Small-Cell%20Lung%20Cancer&author=DP%20Carbone&author=M%20Reck&author=L%20Paz-Ares&author=B%20Creelan&author=L%20Horn&volume=376&issue=25&publication_year=2017&pages=2415-2426&pmid=28636851&doi=10.1056/NEJMoa1613493&?
• What's the financial intake of https://doi.org/10.1093/annonc/mdy006?
• How much income is https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol.&title=PD-1%20blockade%20with%20nivolumab%20in%20endemic%20Kaposi%20sarcoma&author=J%20Delyon&author=A%20Bizot&author=M%20Battistella&author=I%20Madelaine&author=L%20Vercellino&volume=29&issue=4&publication_year=2018&pages=1067-1069&pmid=29324995&doi=10.1093/annonc/mdy006& earning monthly?
• See how much https://doi.org/10.1056/NEJMoa1602252 makes per month
• What's the income of https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med.&title=Nivolumab%20for%20Recurrent%20Squamous-Cell%20Carcinoma%20of%20the%20Head%20and%20Neck&author=RL%20Ferris&author=G%20Blumenschein&author=J%20Fayette&author=J%20Guigay&author=AD%20Colevas&volume=375&issue=19&publication_year=2016&pages=1856-1867&pmid=27718784&doi=10.1056/NEJMoa1602252&?
• What's the financial gain of https://doi.org/10.1001/jamaoncol.2016.0775?
• How much money does https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncol.&title=Safety%20and%20Efficacy%20of%20Nivolumab%20in%20Patients%20With%20Metastatic%20Renal%20Cell%20Carcinoma%20Treated%20Beyond%20Progression:%20A%20Subgroup%20Analysis%20of%20a%20Randomized%20Clinical%20Trial&author=S%20George&author=RJ%20Motzer&author=HJ%20Hammers&author=BG%20Redman&author=TM%20Kuzel&volume=2&issue=9&publication_year=2016&pages=1179-1186&pmid=27243803&doi=10.1001/jamaoncol.2016.0775& generate?
• How much does https://doi.org/10.1056/NEJMoa1510665 earn?
• What's the profit of https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med.&title=Nivolumab%20versus%20Everolimus%20in%20Advanced%20Renal-Cell%20Carcinoma&author=RJ%20Motzer&author=B%20Escudier&author=DF%20McDermott&author=S%20George&author=HJ%20Hammers&volume=373&issue=19&publication_year=2015&pages=1803-1813&pmid=26406148&doi=10.1056/NEJMoa1510665&?
• What is the monthly revenue of https://doi.org/10.1200/JCO.19.00315?
• How much does https://doi.org/10.1056/NEJMc1704612 earn?
• What's the financial intake of https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med.&title=Pembrolizumab%20for%20Advanced%20Urothelial%20Carcinoma&author=J%20Bellmunt&author=DF%20Bajorin&volume=376&issue=23&publication_year=2017&pages=2304&pmid=28591526&doi=10.1056/NEJMc1704612&?
• What's the income of https://doi.org/10.1056/NEJMoa1613683?
• Profit of https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med.&title=Pembrolizumab%20as%20Second-Line%20Therapy%20for%20Advanced%20Urothelial%20Carcinoma&author=J%20Bellmunt&author=R%20de%20Wit&author=DJ%20Vaughn&author=Y%20Fradet&author=JL%20Lee&volume=376&issue=11&publication_year=2017&pages=1015-1026&pmid=28212060&doi=10.1056/NEJMoa1613683&
• How much income is https://doi.org/10.1200/JCO.2016.68.1478 earning monthly?
• How much money does https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol.&title=Antitumor%20Activity%20of%20Pembrolizumab%20in%20Biomarker-Unselected%20Patients%20With%20Recurrent%20and/or%20Metastatic%20Head%20and%20Neck%20Squamous%20Cell%20Carcinoma:%20Results%20From%20the%20Phase%20Ib%20KEYNOTE-012%20Expansion%20Cohort&author=LQ%20Chow&author=R%20Haddad&author=S%20Gupta&author=A%20Mahipal&author=R%20Mehra&volume=34&issue=32&publication_year=2016&pages=3838-3845&pmid=27646946&doi=10.1200/JCO.2016.68.1478& make?
• How much does https://doi.org/10.1056/NEJMoa1501824 bring in each month?
• What's the profit of https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med.&title=Pembrolizumab%20for%20the%20treatment%20of%20non-small-cell%20lung%20cancer&author=EB%20Garon&author=NA%20Rizvi&author=R%20Hui&author=N%20Leighl&author=AS%20Balmanoukian&volume=372&issue=21&publication_year=2015&pages=2018-2028&pmid=25891174&doi=10.1056/NEJMoa1501824&?
• https://doi.org/10.1016/S1470-2045(18)30062-7's total income per month
• Get to know what's the income of https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol.&title=Pembrolizumab%20in%20patients%20with%20thymic%20carcinoma:%20a%20single-arm,%20single-centre,%20phase%202%20study&author=G%20Giaccone&author=C%20Kim&author=J%20Thompson&author=C%20McGuire&author=B%20Kallakury&volume=19&issue=3&publication_year=2018&pages=347-355&pmid=29395863&doi=10.1016/S1470-2045(18)30062-7&
• Income figures for https://doi.org/10.1056/NEJMoa1606774
• How much profit does https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med.&title=Pembrolizumab%20versus%20Chemotherapy%20for%20PD-L1-Positive%20Non-Small-Cell%20Lung%20Cancer&author=M%20Reck&author=D%20Rodriguez-Abreu&author=AG%20Robinson&author=R%20Hui&author=T%20Csoszi&volume=375&issue=19&publication_year=2016&pages=1823-1833&pmid=27718847&doi=10.1056/NEJMoa1606774& generate?
• How much cash flow does https://doi.org/10.1016/S1470-2045(15)00083-2 have monthly?
• Get to know https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol.&title=Pembrolizumab%20versus%20investigator-choice%20chemotherapy%20for%20ipilimumab-refractory%20melanoma%20(KEYNOTE-002):%20a%20randomised,%20controlled,%20phase%202%20trial&author=A%20Ribas&author=I%20Puzanov&author=R%20Dummer&author=D%20Schadendorf&author=O%20Hamid&volume=16&issue=8&publication_year=2015&pages=908-918&pmid=26115796&doi=10.1016/S1470-2045(15)00083-2&'s earnings
• What's https://doi.org/10.1056/NEJMoa1503093's gross income?
• How much does https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med.&title=Pembrolizumab%20versus%20Ipilimumab%20in%20Advanced%20Melanoma&author=C%20Robert&author=J%20Schachter&author=GV%20Long&author=A%20Arance&author=JJ%20Grob&volume=372&issue=26&publication_year=2015&pages=2521-2532&pmid=25891173&doi=10.1056/NEJMoa1503093& bring in each month?
• What's the income generated by https://doi.org/10.1001/jamaoncol.2018.0013 each month?
• How much does https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncol.&title=Safety%20and%20Efficacy%20of%20Pembrolizumab%20Monotherapy%20in%20Patients%20With%20Previously%20Treated%20Advanced%20Gastric%20and%20Gastroesophageal%20Junction%20Cancer:%20Phase%202%20Clinical%20KEYNOTE-059%20Trial&author=CS%20Fuchs&author=T%20Doi&author=RW%20Jang&author=K%20Muro&author=T%20Satoh&volume=4&issue=5&publication_year=2018&pages=e180013&pmid=29543932&doi=10.1001/jamaoncol.2018.0013& gross monthly?
• How much income is https://doi.org/10.1016/S0140-6736(18)31257-1 earning monthly?
• What's the financial outcome of https://scholar.google.com/scholar_lookup?journal=Lancet.&title=Pembrolizumab%20versus%20paclitaxel%20for%20previously%20treated,%20advanced%20gastric%20or%20gastro-oesophageal%20junction%20cancer%20(KEYNOTE-061):%20a%20randomised,%20open-label,%20controlled,%20phase%203%20trial&author=K%20Shitara&author=M%20Ozguroglu&author=YJ%20Bang&author=M%20Di%20Bartolomeo&author=M%20Mandala&volume=392&issue=10142&publication_year=2018&pages=123-133&pmid=29880231&doi=10.1016/S0140-6736(18)31257-1&?
• How much revenue does https://doi.org/10.1016/S0140-6736(17)31827-5 bring in?
• How much profit does https://scholar.google.com/scholar_lookup?journal=Lancet.&title=Nivolumab%20in%20patients%20with%20advanced%20gastric%20or%20gastro-oesophageal%20junction%20cancer%20refractory%20to,%20or%20intolerant%20of,%20at%20least%20two%20previous%20chemotherapy%20regimens%20(ONO-4538-12,%20ATTRACTION-2):%20a%20randomised,%20double-blind,%20placebo-controlled,%20phase%203%20trial&author=YK%20Kang&author=N%20Boku&author=T%20Satoh&author=MH%20Ryu&author=Y%20Chao&volume=390&issue=10111&publication_year=2017&pages=2461-2471&pmid=28993052&doi=10.1016/S0140-6736(17)31827-5& generate?
• How much profit does https://doi.org/10.1016/S0140-6736(16)00561-4 generate?
• Revenue of https://scholar.google.com/scholar_lookup?journal=Lancet.&title=Atezolizumab%20in%20patients%20with%20locally%20advanced%20and%20metastatic%20urothelial%20carcinoma%20who%20have%20progressed%20following%20treatment%20with%20platinum-based%20chemotherapy:%20a%20single-arm,%20multicentre,%20phase%202%20trial&author=JE%20Rosenberg&author=J%20Hoffman-Censits&author=T%20Powles&author=MS%20van%20der%20Heijden&author=AV%20Balar&volume=387&issue=10031&publication_year=2016&pages=1909-1920&pmid=26952546&doi=10.1016/S0140-6736(16)00561-4&
• What is the monthly revenue of https://doi.org/10.1016/S0140-6736(16)32517-X?
• How much profit does https://scholar.google.com/scholar_lookup?journal=Lancet.&title=Atezolizumab%20versus%20docetaxel%20in%20patients%20with%20previously%20treated%20non-small-cell%20lung%20cancer%20(OAK):%20a%20phase%203,%20open-label,%20multicentre%20randomised%20controlled%20trial&author=A%20Rittmeyer&author=F%20Barlesi&author=D%20Waterkamp&author=K%20Park&author=F%20Ciardiello&volume=389&issue=10066&publication_year=2017&pages=255-265&pmid=27979383&doi=10.1016/S0140-6736(16)32517-X& generate?
• What's the income generated by https://doi.org/10.1016/S0140-6736(16)00587-0 each month?
• What are the earnings of https://scholar.google.com/scholar_lookup?journal=Lancet.&title=Atezolizumab%20versus%20docetaxel%20for%20patients%20with%20previously%20treated%20non-small-cell%20lung%20cancer%20(POPLAR):%20a%20multicentre,%20open-label,%20phase%202%20randomised%20controlled%20trial&author=L%20Fehrenbacher&author=A%20Spira&author=M%20Ballinger&author=M%20Kowanetz&author=J%20Vansteenkiste&volume=387&issue=10030&publication_year=2016&pages=1837-1846&pmid=26970723&doi=10.1016/S0140-6736(16)00587-0&?
• How profitable is https://doi.org/10.1200/JCO.2016.71.9476?
• What's the revenue for https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol.&title=Phase%20II%20Trial%20of%20Atezolizumab%20As%20First-Line%20or%20Subsequent%20Therapy%20for%20Patients%20With%20Programmed%20Death-Ligand%201-Selected%20Advanced%20Non-Small-Cell%20Lung%20Cancer%20(BIRCH)&author=S%20Peters&author=S%20Gettinger&author=ML%20Johnson&author=PA%20Janne&author=MC%20Garassino&volume=35&issue=24&publication_year=2017&pages=2781-2789&pmid=28609226&doi=10.1200/JCO.2016.71.9476&?
• Find out how much https://doi.org/10.1016/S1470-2045(16)30364-3 earns monthly
• How much does https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol.&title=Avelumab%20in%20patients%20with%20chemotherapy-refractory%20metastatic%20Merkel%20cell%20carcinoma:%20a%20multicentre,%20single-group,%20open-label,%20phase%202%20trial&author=HL%20Kaufman&author=J%20Russell&author=O%20Hamid&author=S%20Bhatia&author=P%20Terheyden&volume=17&issue=10&publication_year=2016&pages=1374-1385&pmid=27592805&doi=10.1016/S1470-2045(16)30364-3& make?
• See how much https://doi.org/10.1056/NEJMoa1709937 makes per month
• How much money does https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med.&title=Durvalumab%20after%20Chemoradiotherapy%20in%20Stage%20III%20Non-Small-Cell%20Lung%20Cancer&author=SJ%20Antonia&author=A%20Villegas&author=D%20Daniel&author=D%20Vicente&author=S%20Murakami&volume=377&issue=20&publication_year=2017&pages=1919-1929&pmid=28885881&doi=10.1056/NEJMoa1709937& make?
• How much does https://doi.org/10.1001/jamaoncol.2017.2411 rake in every month?
• Get to know what's the income of https://doi.org/10.1056/NEJMoa1805131
• How much income is https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med.&title=PD-1%20Blockade%20with%20Cemiplimab%20in%20Advanced%20Cutaneous%20Squamous-Cell%20Carcinoma&author=MR%20Migden&author=D%20Rischin&author=CD%20Schmults&author=A%20Guminski&author=A%20Hauschild&volume=379&issue=4&publication_year=2018&pages=341-351&pmid=29863979&doi=10.1056/NEJMoa1805131& earning monthly?
• How much does https://doi.org/10.1200/JCO.19.00318 pull in monthly?
• What is the earnings of https://doi.org/10.1016/1074-7613(95)90125-6?
• How much revenue does https://scholar.google.com/scholar_lookup?journal=Immunity.&title=Loss%20of%20CTLA-4%20leads%20to%20massive%20lymphoproliferation%20and%20fatal%20multiorgan%20tissue%20destruction,%20revealing%20a%20critical%20negative%20regulatory%20role%20of%20CTLA-4&author=EA%20Tivol&author=F%20Borriello&author=AN%20Schweitzer&author=WP%20Lynch&author=JA%20Bluestone&volume=3&issue=5&publication_year=1995&pages=541-547&pmid=7584144&doi=10.1016/1074-7613(95)90125-6& bring in?
• What's the financial gain of https://doi.org/10.1016/S1471-4906(01)01888-9?
• How much does https://scholar.google.com/scholar_lookup?journal=Trends%20Immunol.&title=PD-1:%20an%20inhibitory%20immunoreceptor%20involved%20in%20peripheral%20tolerance&author=H%20Nishimura&author=T%20Honjo&volume=22&issue=5&publication_year=2001&pages=265-268&pmid=11323285&doi=10.1016/S1471-4906(01)01888-9& net monthly?
• How much does https://doi.org/10.1056/NEJMoa1302369 pull in?
• How much profit does https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med.&title=Nivolumab%20plus%20ipilimumab%20in%20advanced%20melanoma&author=JD%20Wolchok&author=H%20Kluger&author=MK%20Callahan&author=MA%20Postow&author=NA%20Rizvi&volume=369&issue=2&publication_year=2013&pages=122-133&pmid=23724867&doi=10.1056/NEJMoa1302369& make?
• Monthly income for https://doi.org/10.1056/NEJMoa1414428
• Get to know what's the income of https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med.&title=Nivolumab%20and%20ipilimumab%20versus%20ipilimumab%20in%20untreated%20melanoma&author=MA%20Postow&author=J%20Chesney&author=AC%20Pavlick&author=C%20Robert&author=K%20Grossmann&volume=372&issue=21&publication_year=2015&pages=2006-2017&pmid=25891304&doi=10.1056/NEJMoa1414428&
• How much does https://doi.org/10.1056/NEJMoa1504030 pull in monthly?
• What's the monthly income of https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med.&title=Combined%20Nivolumab%20and%20Ipilimumab%20or%20Monotherapy%20in%20Untreated%20Melanoma&author=J%20Larkin&author=V%20Chiarion-Sileni&author=R%20Gonzalez&author=JJ%20Grob&author=CL%20Cowey&volume=373&issue=1&publication_year=2015&pages=23-34&pmid=26027431&doi=10.1056/NEJMoa1504030&?
• How much does https://doi.org/10.1056/NEJMoa1709684 pull in?
• What's the financial outcome of https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med.&title=Overall%20Survival%20with%20Combined%20Nivolumab%20and%20Ipilimumab%20in%20Advanced%20Melanoma&author=JD%20Wolchok&author=V%20Chiarion-Sileni&author=R%20Gonzalez&author=P%20Rutkowski&author=JJ%20Grob&volume=377&issue=14&publication_year=2017&pages=1345-1356&pmid=28889792&doi=10.1056/NEJMoa1709684&?
• Financial intake of https://doi.org/10.1016/S1470-2045(18)30700-9
• How much does https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol.&title=Nivolumab%20plus%20ipilimumab%20or%20nivolumab%20alone%20versus%20ipilimumab%20alone%20in%20advanced%20melanoma%20(CheckMate%20067):%204-year%20outcomes%20of%20a%20multicentre,%20randomised,%20phase%203%20trial&author=FS%20Hodi&author=V%20Chiarion-Sileni&author=R%20Gonzalez&author=JJ%20Grob&author=P%20Rutkowski&volume=19&issue=11&publication_year=2018&pages=1480-1492&pmid=30361170&doi=10.1016/S1470-2045(18)30700-9& gross monthly?
• How much does https://doi.org/10.1016/S1470-2045(17)30428-X gross monthly?
• Financial intake of https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol.&title=Standard-dose%20pembrolizumab%20in%20combination%20with%20reduced-dose%20ipilimumab%20for%20patients%20with%20advanced%20melanoma%20(KEYNOTE-029):%20an%20open-label,%20phase%201b%20trial&author=GV%20Long&author=V%20Atkinson&author=JS%20Cebon&author=MB%20Jameson&author=BM%20Fitzharris&volume=18&issue=9&publication_year=2017&pages=1202-1210&pmid=28729151&doi=10.1016/S1470-2045(17)30428-X&
• Explore the financials of https://doi.org/10.1056/NEJMoa1805453
• How much income is https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med.&title=Combined%20Nivolumab%20and%20Ipilimumab%20in%20Melanoma%20Metastatic%20to%20the%20Brain&author=HA%20Tawbi&author=PA%20Forsyth&author=A%20Algazi&author=O%20Hamid&author=FS%20Hodi&volume=379&issue=8&publication_year=2018&pages=722-730&pmid=30134131&doi=10.1056/NEJMoa1805453& earning monthly?
• What's the income of https://doi.org/10.1016/S1470-2045(16)30126-7?
• How much revenue does https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol.&title=Sequential%20administration%20of%20nivolumab%20and%20ipilimumab%20with%20a%20planned%20switch%20in%20patients%20with%20advanced%20melanoma%20(CheckMate%20064):%20an%20open-label,%20randomised,%20phase%202%20trial&author=JS%20Weber&author=G%20Gibney&author=RJ%20Sullivan&author=JA%20Sosman&author=CL%20Slingluff&volume=17&issue=7&publication_year=2016&pages=943-955&pmid=27269740&doi=10.1016/S1470-2045(16)30126-7& bring in?
• Get to know https://doi.org/10.1016/S1470-2045(16)30366-7's earnings
• What is the monthly revenue of https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol.&title=Combined%20nivolumab%20and%20ipilimumab%20versus%20ipilimumab%20alone%20in%20patients%20with%20advanced%20melanoma:%202-year%20overall%20survival%20outcomes%20in%20a%20multicentre,%20randomised,%20controlled,%20phase%202%20trial&author=FS%20Hodi&author=J%20Chesney&author=AC%20Pavlick&author=C%20Robert&author=KF%20Grossmann&volume=17&issue=11&publication_year=2016&pages=1558-1568&pmid=27622997&doi=10.1016/S1470-2045(16)30366-7&?
• What's the income of https://doi.org/10.1093/annonc/mdw692?
• See how much https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol.&title=Short-term%20CTLA-4%20blockade%20directly%20followed%20by%20PD-1%20blockade%20in%20advanced%20melanoma%20patients:%20a%20single-center%20experience&author=A%20Meerveld-Eggink&author=EA%20Rozeman&author=F%20Lalezari&author=JV%20van%20Thienen&author=J%20Haanen&volume=28&issue=4&publication_year=2017&pages=862-867&pmid=28158487&doi=10.1093/annonc/mdw692& makes per month
• What's the income of https://doi.org/10.1016/j.ejca.2016.07.003?
• https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Cancer.&title=Combined%20low-dose%20ipilimumab%20and%20pembrolizumab%20after%20sequential%20ipilimumab%20and%20pembrolizumab%20failure%20in%20advanced%20melanoma&author=MC%20Kirchberger&author=A%20Hauschild&author=G%20Schuler&author=L%20Heinzerling&volume=65&publication_year=2016&pages=182-184&pmid=27501507&doi=10.1016/j.ejca.2016.07.003&'s revenue stream
• What's the monthly income of https://doi.org/10.1200/JCO.2016.67.9258?
• How much profit does https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol.&title=Efficacy%20and%20Safety%20of%20Nivolumab%20Alone%20or%20in%20Combination%20With%20Ipilimumab%20in%20Patients%20With%20Mucosal%20Melanoma:%20A%20Pooled%20Analysis&author=SP%20D'Angelo&author=J%20Larkin&author=JA%20Sosman&author=C%20Lebbe&author=B%20Brady&volume=35&issue=2&publication_year=2017&pages=226-235&pmid=28056206&doi=10.1200/JCO.2016.67.9258& generate?
• What's the income of https://doi.org/10.18632/oncotarget.25627?
• How much revenue does https://scholar.google.com/scholar_lookup?journal=Oncotarget.&title=Real%20world%20experience%20in%20low-dose%20ipilimumab%20in%20combination%20with%20PD-1%20blockade%20in%20advanced%20melanoma%20patients&author=MC%20Kirchberger&author=A%20Moreira&author=M%20Erdmann&author=G%20Schuler&author=L%20Heinzerling&volume=9&issue=48&publication_year=2018&pages=28903-28909&pmid=29988983&doi=10.18632/oncotarget.25627& produce monthly?
• Profit of https://doi.org/10.1038/s41591-018-0198-0
• How much revenue does https://scholar.google.com/scholar_lookup?journal=Nat%20Med.&title=Neoadjuvant%20versus%20adjuvant%20ipilimumab%20plus%20nivolumab%20in%20macroscopic%20stage%20III%20melanoma&author=CU%20Blank&author=EA%20Rozeman&author=LF%20Fanchi&author=K%20Sikorska&author=B%20van%20de%20Wiel&volume=24&issue=11&publication_year=2018&pages=1655-1661&pmid=30297911&doi=10.1038/s41591-018-0198-0& bring in?
• Get to know what's the income of https://doi.org/10.1200/JCO.2016.72.1985
• How much income does https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol.&title=Safety%20and%20Efficacy%20of%20Nivolumab%20in%20Combination%20With%20Ipilimumab%20in%20Metastatic%20Renal%20Cell%20Carcinoma:%20The%20CheckMate%20016%20Study&author=HJ%20Hammers&author=ER%20Plimack&author=JR%20Infante&author=BI%20Rini&author=DF%20McDermott&volume=35&issue=34&publication_year=2017&pages=3851-3858&pmid=28678668&doi=10.1200/JCO.2016.72.1985& have?
• https://doi.org/10.1056/NEJMoa1712126 income
• Financial intake of https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med.&title=Nivolumab%20plus%20Ipilimumab%20versus%20Sunitinib%20in%20Advanced%20Renal-Cell%20Carcinoma&author=RJ%20Motzer&author=NM%20Tannir&author=DF%20McDermott&author=O%20Aren%20Frontera&author=B%20Melichar&volume=378&issue=14&publication_year=2018&pages=1277-1290&pmid=29562145&doi=10.1056/NEJMoa1712126&
• Learn how profitable https://doi.org/10.1016/S1470-2045(18)30778-2 is on a monthly basis
• https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol.&title=Patient-reported%20outcomes%20of%20patients%20with%20advanced%20renal%20cell%20carcinoma%20treated%20with%20nivolumab%20plus%20ipilimumab%20versus%20sunitinib%20(CheckMate%20214):%20a%20randomised,%20phase%203%20trial&author=D%20Cella&author=V%20Grunwald&author=B%20Escudier&author=HJ%20Hammers&author=S%20George&volume=20&issue=2&publication_year=2019&pages=297-310&pmid=30658932&doi=10.1016/S1470-2045(18)30778-2&'s revenue stream
• How much does https://doi.org/10.1016/S1470-2045(17)30422-9 generate monthly?
• Financial intake of https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol.&title=Nivolumab%20in%20patients%20with%20metastatic%20DNA%20mismatch%20repair-deficient%20or%20microsatellite%20instability-high%20colorectal%20cancer%20(CheckMate%20142):%20an%20open-label,%20multicentre,%20phase%202%20study&author=MJ%20Overman&author=R%20McDermott&author=JL%20Leach&author=S%20Lonardi&author=HJ%20Lenz&volume=18&issue=9&publication_year=2017&pages=1182-1191&pmid=28734759&doi=10.1016/S1470-2045(17)30422-9&
• What's the monthly money flow for https://doi.org/10.1200/JCO.2017.76.9901?
• Get to know what's the income of https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol.&title=Durable%20Clinical%20Benefit%20With%20Nivolumab%20Plus%20Ipilimumab%20in%20DNA%20Mismatch%20Repair-Deficient/Microsatellite%20Instability-High%20Metastatic%20Colorectal%20Cancer&author=MJ%20Overman&author=S%20Lonardi&author=KYM%20Wong&author=HJ%20Lenz&author=F%20Gelsomino&volume=36&issue=8&publication_year=2018&pages=773-779&pmid=29355075&doi=10.1200/JCO.2017.76.9901&
• What's the financial intake of https://doi.org/10.1016/S1470-2045(15)00544-6?
• How much profit is https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol.&title=Safety%20and%20antitumour%20activity%20of%20durvalumab%20plus%20tremelimumab%20in%20non-small%20cell%20lung%20cancer:%20a%20multicentre,%20phase%201b%20study&author=S%20Antonia&author=SB%20Goldberg&author=A%20Balmanoukian&author=JE%20Chaft&author=RE%20Sanborn&volume=17&issue=3&publication_year=2016&pages=299-308&pmid=26858122&doi=10.1016/S1470-2045(15)00544-6& making per month?
• What is the monthly revenue of https://doi.org/10.1016/S1470-2045(16)30624-6?
• Check the income stats for https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol.&title=Nivolumab%20plus%20ipilimumab%20as%20first-line%20treatment%20for%20advanced%20non-small-cell%20lung%20cancer%20(CheckMate%20012):%20results%20of%20an%20open-label,%20phase%201,%20multicohort%20study&author=MD%20Hellmann&author=NA%20Rizvi&author=JW%20Goldman&author=SN%20Gettinger&author=H%20Borghaei&volume=18&issue=1&publication_year=2017&pages=31-41&pmid=27932067&doi=10.1016/S1470-2045(16)30624-6&
• How much does https://doi.org/10.1056/NEJMoa1801946 make?
• Get to know https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med.&title=Nivolumab%20plus%20Ipilimumab%20in%20Lung%20Cancer%20with%20a%20High%20Tumor%20Mutational%20Burden&author=MD%20Hellmann&author=TE%20Ciuleanu&author=A%20Pluzanski&author=JS%20Lee&author=GA%20Otterson&volume=378&issue=22&publication_year=2018&pages=2093-2104&pmid=29658845&doi=10.1056/NEJMoa1801946&'s earnings
• Discover the revenue of https://doi.org/10.1200/JCO.18.01042
• Discover the revenue of https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol.&title=First-Line%20Nivolumab%20Plus%20Ipilimumab%20in%20Advanced%20Non-Small-Cell%20Lung%20Cancer%20(CheckMate%20568):%20Outcomes%20by%20Programmed%20Death%20Ligand%201%20and%20Tumor%20Mutational%20Burden%20as%20Biomarkers&author=N%20Ready&author=MD%20Hellmann&author=MM%20Awad&author=GA%20Otterson&author=M%20Gutierrez&volume=37&issue=12&publication_year=2019&pages=992-1000&pmid=30785829&doi=10.1200/JCO.18.01042&
• How much does https://doi.org/10.1016/S1470-2045(16)30098-5 pull in?
• How much does https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol.&title=Nivolumab%20alone%20and%20nivolumab%20plus%20ipilimumab%20in%20recurrent%20small-cell%20lung%20cancer%20(CheckMate%20032):%20a%20multicentre,%20open-label,%20phase%201/2%20trial&author=SJ%20Antonia&author=JA%20Lopez-Martin&author=J%20Bendell&author=PA%20Ott&author=M%20Taylor&volume=17&issue=7&publication_year=2016&pages=883-895&pmid=27269741&doi=10.1016/S1470-2045(16)30098-5& generate monthly?
• What are the total earnings of https://doi.org/10.1016/S2213-2600(18)30420-X?
• How much profit does https://scholar.google.com/scholar_lookup?journal=Lancet%20Respir%20Med.&title=Ipilimumab%20and%20nivolumab%20in%20the%20treatment%20of%20recurrent%20malignant%20pleural%20mesothelioma%20(INITIATE):%20results%20of%20a%20prospective,%20single-arm,%20phase%202%20trial&author=MJ%20Disselhorst&author=J%20Quispel-Janssen&author=F%20Lalezari&author=K%20Monkhorst&author=JF%20de%20Vries&volume=7&issue=3&publication_year=2019&pages=260-270&pmid=30660511&doi=10.1016/S2213-2600(18)30420-X& make?
• Explore the financials of https://doi.org/10.1016/S1470-2045(18)30765-4
• What's the financial gain of https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol.&title=Nivolumab%20or%20nivolumab%20plus%20ipilimumab%20in%20patients%20with%20relapsed%20malignant%20pleural%20mesothelioma%20(IFCT-1501%20MAPS2):%20a%20multicentre,%20open-label,%20randomised,%20non-comparative,%20phase%202%20trial&author=A%20Scherpereel&author=J%20Mazieres&author=L%20Greillier&author=S%20Lantuejoul&author=P%20Do&volume=20&issue=2&publication_year=2019&pages=239-253&pmid=30660609&doi=10.1016/S1470-2045(18)30765-4&?
• What's the income generated by https://doi.org/10.1200/JCO.2017.76.6212 each month?
• What are the earnings of https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Oncol.&title=CheckMate-032%20Study:%20Efficacy%20and%20Safety%20of%20Nivolumab%20and%20Nivolumab%20Plus%20Ipilimumab%20in%20Patients%20With%20Metastatic%20Esophagogastric%20Cancer&author=YY%20Janjigian&author=J%20Bendell&author=E%20Calvo&author=JW%20Kim&author=PA%20Ascierto&volume=36&issue=28&publication_year=2018&pages=2836-2844&pmid=30110194&doi=10.1200/JCO.2017.76.6212&?
• What's the monthly money flow for https://doi.org/10.18632/oncotarget.25564?
• What's the income generated by https://scholar.google.com/scholar_lookup?journal=Oncotarget.&title=Ipilimumab%20plus%20nivolumab%20and%20DNA-repair%20defects%20in%20AR-V7-expressing%20metastatic%20prostate%20cancer&author=K%20Boudadi&author=DL%20Suzman&author=V%20Anagnostou&author=W%20Fu&author=B%20Luber&volume=9&issue=47&publication_year=2018&pages=28561-28571&pmid=29983880&doi=10.18632/oncotarget.25564& each month?
• How profitable is https://doi.org/10.1016/S1470-2045(18)30006-8?
• How much does https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol.&title=Nivolumab%20with%20or%20without%20ipilimumab%20treatment%20for%20metastatic%20sarcoma%20(Alliance%20A091401):%20two%20open-label,%20non-comparative,%20randomised,%20phase%202%20trials&author=SP%20D'Angelo&author=MR%20Mahoney&author=BA%20Van%20Tine&author=J%20Atkins&author=MM%20Milhem&volume=19&issue=3&publication_year=2018&pages=416-426&pmid=29370992&doi=10.1016/S1470-2045(18)30006-8& rake in every month?
• How much does https://doi.org/10.1056/NEJMoa1609214 rake in every month?
• How much does https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med.&title=Fulminant%20Myocarditis%20with%20Combination%20Immune%20Checkpoint%20Blockade&author=DB%20Johnson&author=JM%20Balko&author=ML%20Compton&author=S%20Chalkias&author=J%20Gorham&volume=375&issue=18&publication_year=2016&pages=1749-1755&pmid=27806233&doi=10.1056/NEJMoa1609214& earn?
• Get to know what's the income of https://doi.org/10.1097/CMR.0000000000000251
• How much revenue does https://scholar.google.com/scholar_lookup?journal=Melanoma%20Res.&title=Myocarditis%20as%20an%20immune-related%20adverse%20event%20with%20ipilimumab/nivolumab%20combination%20therapy%20for%20metastatic%20melanoma&author=A%20Mehta&author=A%20Gupta&author=F%20Hannallah&author=T%20Koshy&author=S%20Reimold&volume=26&issue=3&publication_year=2016&pages=319-320&pmid=27110676&doi=10.1097/CMR.0000000000000251& generate?
• Monthly income for https://doi.org/10.1136/annrheumdis-2016-209595
• How much does https://scholar.google.com/scholar_lookup?journal=Ann%20Rheum%20Dis.&title=Inflammatory%20arthritis%20and%20sicca%20syndrome%20induced%20by%20nivolumab%20and%20ipilimumab&author=LC%20Cappelli&author=AK%20Gutierrez&author=AN%20Baer&author=J%20Albayda&author=RL%20Manno&volume=76&issue=1&publication_year=2017&pages=43-50&pmid=27307501&doi=10.1136/annrheumdis-2016-209595& earn?
• What's the financial gain of https://github.com/ncbi?
• What is the monthly revenue of https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508, -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508! 4d-77.0988323?
• What are the total earnings of https://www.nlm.nih.gov/web_policies.html?
• What's the revenue for https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office?
• What's the monthly income of https://www.hhs.gov/vulnerability-disclosure-policy/index.html?
• Learn how profitable https://support.nlm.nih.gov/?pagename=cloudpmc-viewer%3Apmc%3Aarticle%3Ajournal is on a monthly basis
• What's the revenue for https://www.nlm.nih.gov/accessibility.html?
• How profitable is https://www.nlm.nih.gov/careers/careers.html?
• What's the profit of https://www.nlm.nih.gov/?
• What's https://www.nih.gov/'s gross income?
• How much does https://www.hhs.gov/ make?
• See how much https://www.usa.gov/ makes per month

Analytics and Tracking {📊}

• Google Analytics
• Google Analytics 4
• Google Tag Manager

Libraries {📚}

• jQuery
• jQuery module (jquery-3.6.0)
• Zoom.js

Emails and Hosting {✉️}

Mail Servers:

• nihcesxway.hub.nih.gov
• nihcesxway2.hub.nih.gov
• nihcesxway3.hub.nih.gov
• nihcesxway4.hub.nih.gov
• nihcesxway5.hub.nih.gov

Name Servers:

• dns1-ncbi.ncbi.nlm.nih.gov
• dns2-ncbi.ncbi.nlm.nih.gov
• lhcns1.nlm.nih.gov
• lhcns2.nlm.nih.gov

CDN Services {📦}

• Ncbi